急性冠脉综合征患者出院后新型P2Y12抑制剂一年疗效与安全性:ACHILLES登记研究
基于前瞻性多中心ACHILLES登记,分析1717例ACS出院患者,比较新型口服P2Y12抑制剂与氯吡格雷的临床特征及1年预后。新型P2Y12抑制剂使用与较低全因死亡和MACE风险独立相关,大出血无差异,但氯吡格雷仍最常用于老年和高危患者。
要点
- ACS出院时使用新型P2Y12抑制剂与较低全因死亡和MACE风险独立相关。
- 新型P2Y12抑制剂与氯吡格雷相比大出血事件无显著差异。
- 氯吡格雷仍最常用于老年和高危ACS患者。
核心结论
- 在当前临床实践的ACS登记中,出院时使用新型口服P2Y12抑制剂与较低的全因死亡和MACE风险独立相关,且不增加大出血。
- 氯吡格雷仍是ACS患者最常用的P2Y12抑制剂,尤其在老年和高危患者中。
研究设计与样本
- ACHILLES登记为观察性、前瞻性、多中心注册研究,纳入ACS出院患者。
- 共1717例连续患者,其中1294例(75.4%)出院时使用P2Y12抑制剂且未联合口服抗凝药。
- 47%的患者使用了新型口服P2Y12抑制剂。
- 随访1年,分析缺血和主要出血事件,采用多因素Cox回归和Kaplan-Meier曲线。
主要发现
- 随访1年,64例(5.0%/年)发生新发心肌梗死,127例(10.0%/年)发生MACE,78例(6.1%/年)死亡。
临床怎么用
- 对于ACS出院患者,在无口服抗凝指征时,可考虑优先选用新型口服P2Y12抑制剂以降低缺血事件风险。
- 老年和高危ACS患者中氯吡格雷使用比例高,临床决策需综合评估缺血与出血风险。
局限性
- 本研究为观察性登记研究,存在选择偏倚和未测量混杂因素的可能。
- 氯吡格雷组患者基线风险更高,可能影响组间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prasugrel and ticagrelor have demonstrated higher efficacy than clopidogrel in their main clinical trials for patients with acute coronary syndrome (ACS). However, the long-term prognosis and different clinical characteristics related to the type of antiplatelet prescription in current clinical practice ACS patients have not been analysed in depth. The objective of this study was to analyse the clinical profile of ACS and the efficacy and safety of novel oral P2Y12 inhibitors in current clinical practice patients discharged afterACS. METHODS: We collected data from the ACHILLES registry, and an observational, prospective and multicentre registry of patients discharged after ACS. We analysed baseline characteristics, clinical profile and therapy during ACS admission and compared with the different treatments at discharge. After 1 year of follow-up, ischaemic and major bleeding events were analysed. Multivariate Cox regression analysis and Kaplan Meier curves were also plotted. RESULTS: Of 1717 consecutive patients, 1294 (75.4%) were discharged with a P2Y12 inhibitor without oral anticoagulation. Novel oral P2Y12 inhibitors were indicated in 47%. Patients treated with clopidogrel were elderly (69.1 ± 13.4 vs 60.4 ± 11.5 years; P < .001) and had a higher prevalence of cardiovascular risk factors. GRACE and CRUSADE scores were higher in the clopidogrel than in novel oral P2Y12 inhibitors group (P < .001). After 1 year of follow-up, 64(5.0%/year) patients had a new myocardial infarction, 127(10.0%/year) had a major adverse cardiovascular event (MACE) and 78(6.1%/year) died. Patients treated with clopidogrel had a significantly higher annual rate of cardiovascular mortality, MACE and all-cause mortality (allP < .001) without differences in major bleeding (P = .587) compared with novel oral P2Y12 inhibitors. After multivariate adjustment for the main clinical variables related to adverse prognosis in ACS patients, the discharge with novel oral P2Y12 inhibitors therapy was independently associated with lower risk of all-cause mortality (HR0.49, 95% CI [0.24-0.98], P = .044) and lower risk of MACE (HR0.64, 95% CI [0.41-0.98], P = .044). CONCLUSIONS: In this prospective, observational and current clinical practice ACS registry, the use of novel oral P2Y12 inhibitors was associated with a reduction in adverse events compared with clopidogrel in patients with ACS. Novel oral P2Y12 inhibitors prescription at discharge was independently associated with lower all-cause mortality and MACE without differences in bleeding events. However, clopidogrel remained the most common P2Y12 inhibitor employed for ACS, especially in older and high-risk patients.
引用
- Ruiz-Nodar JM, Esteve-Pastor MA, Rivera-Caravaca JM, et al. One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry. Br J Clin Pharmacol. 2020. PMID: 31912949. doi:10.1111/bcp.14213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。